Recognition Memory and Verbal Fluency Differentiate Probable Alzheimer Disease From Subcortical Ischemic Vascular Dementia

Mary C. Tierney, PhD; Sandra E. Black, MD; John P. Szalai, PhD; W. Gary Snow, PhD; Rory H. Fisher, MB; Grant Nadon, MD; Helena C. Chui, MD

Background: Alzheimer disease (AD) and vascular dementia are among the most frequently occurring causes of dementia in the world, and their accurate differentiation is important because different pharmaceutical strategies may modify the course of each disease.

Objective: To determine which of 10 neuropsychological test scores can accurately differentiate patients with probable AD from those with subcortical ischemic vascular dementia (SIVD) for use in evidence-based clinical practice.

Design: Patients with suspected dementia were referred to the study by family physicians, geriatricians, and neurologists. All participants received a thorough assessment according to standard diagnostic guidelines. Diagnoses of probable AD (n=31) and probable SIVD (n=31) were made according to consensus criteria. The diagnosticians were blind to the results of the 10 neuropsychological test scores.

Results: There were no significant differences between the groups in age or Mini-Mental State Examination scores. Logistic regression analyses identified 2 neuropsychological tests that best distinguished the groups (sensitivity=81%; specificity=84%; positive likelihood ratio=5.1). These were the recognition memory subtest of the Rey Auditory Verbal Learning Test and the Controlled Oral Word Association Test. The AD group performed better on the oral association test, whereas the SIVD group did better on the recognition memory test.

Conclusion: Patients with probable AD and probable SIVD can be distinguished with a high degree of accuracy using these 2 neuropsychological tests.

Arch Neurol. 2001;58:1654-1659
PARTICIPANTS AND METHODS

Participants with suspected dementia were referred to the study by family physicians, geriatricians, and neurologists. Figure 1 shows a flow diagram describing the number of participants referred to the study and those meeting inclusion and exclusion criteria. Physicians were asked to refer patients with suspected AD or VaD who did not have any other medical conditions that would account for the cognitive impairment. Informed consent was obtained after the nature of the procedures had been fully explained. An experienced board-certified geriatrician (R.H.F. or G.N.) saw the patients and their caregivers. A standardized interview was administered inquiring about the history and course of cognitive problems as well as daily functioning. A thorough physical examination, a head CT scan, and laboratory tests including hematological, renal, hepatic, and metabolic function tests were conducted. To be included in this study, participants were required to be 60 years or older. The final study sample was selected according to the fulfillment of (1) medical exclusion criteria; (2) dementia inclusion criteria; and (3) dementia subtype inclusion criteria.

MEDICAL EXCLUSION CRITERIA

We excluded patients with severe aphasia because of their inability to complete neuropsychological testing. We also excluded subjects if any of the following causes of memory impairment other than AD or VaD were present: chronic alcohol abuse, hypoxia, metabolic disorders, intracranial mass lesions, psychoses, brain trauma, or other neurological disorders including Parkinson disease. Six patients were excluded because they met these medical exclusion criteria.

RESULTS

STUDY SAMPLE

The demographic characteristics of patients in the AD and SIVD groups, as well as their scores on the Mini-Mental State Examination (MMSE), the original full-scale Hachinski Ischemic Scale, and the neuropsychological tests are presented in Table 1. There were no differences between the groups in age (t60=0.42; P=.68), level of education (t60=1.86; P=.07), or MMSE score (t60=0.66; P=.51). However, because the educational differences between the groups were marginally significant and because these differences are known to influence cognitive performance, education was used as a covariate in all subsequent analyses. As expected, the mean difference between the groups on the Hachinski Ischemic Scale was significant (t58;1 =13.99; P=.001).

All patients in the SIVD group had subcortical involvement including the basal ganglia (caudate or lenticular nucleus), thalamus, internal capsule, and periventricular white matter region. Nineteen subjects had purely subcortical infarcts (pure SIVD). Twelve had cortical lesions with involvement of the adjacent white matter in addition to subcortical lesions (mixed SIVD). Of the 31 patients in the SIVD group, 9 had unilateral lesions and 22 had bilateral lesions.

NEUROPSYCHOLOGICAL DIFFERENCES BETWEEN PARTICIPANTS WITH VAD AND AD

Logistic regression analysis (forward stepwise procedure) was used to determine which of the tests in the full

©2001 American Medical Association. All rights reserved.
Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) guidelines. Two patients who met these criteria were excluded because of the presence of vascular lesions on the CT scan. Thirty-one patients met the criteria of the NINCDS-ADRDA for probable AD.

SIVD Group

To be included in this group, participants had to meet National Institute of Neurological Disorders and Stroke—Association Internationale pour la Recherche et l’Enseignement en Neurosciences (NINDS-AIREN) criteria for probable VaD, modified for SIVD by restricting the group to patients with evidence of lacunar infarct. Specifically, patients were included if they had neuroimaging evidence of a subcortical ischemic infarct with a clear temporal relationship between the stroke and the onset of dementia. Four patients were excluded because there was no evidence of subcortical infarcts on the CT scan. One participant was excluded because of the presence of a meningioma on the CT scan. Patients were also restricted from participation if they had experienced only hemorrhagic strokes or exhibited only periventricular white matter disease on neuroimaging studies. Two subjects were excluded because of brain hemorrhages. No patients in this sample had infarcts limited to the cortical regions. In cases where there was a report of vascular lesions, the film was independently reviewed by the study neurologist (S.E.B.), who was experienced in clinical and research neuroimaging and had no knowledge of the clinical histories or test performance of the patients. Lesions were classified as subcortical or both subcortical and cortical (mixed), and the lobe or subcortical location was documented noting particularly strategic locations in the thalamus, angular gyrus, and medial temporal regions. Thirty-one patients met the criteria for SIVD.

Neuropsychological Tests to Differentiate AD vs SIVD

After the administration of the dementia screen, another research battery of neuropsychological tests, distinct from that used to diagnose dementia, was given to participants. The psychometricists who administered the tests were blind to the diagnoses of the participants. This battery was administered to compare the 2 groups and was kept separate from any diagnostic decisions. It consisted of the following 10 neuropsychological test scores: Wechsler Memory Scale subtests; Mental Control, Logical Memory, and Paired Associates; the Rey Auditory Verbal Learning Test (RAVLT); total number of words recalled after an interference list (delayed recall), and percentage of true positives and true negatives from a 30-item recognition list; COWAT; number of words beginning with F, A, and S generated in 1 minute for each letter; and the Trail Making Test (intermediate form): time taken to complete parts A and B.

STATISTICAL ANALYSES

Logistic regression analysis was used to examine the significance of the model, which included the 10 neuropsychological test scores and the covariate of education, for the prediction of membership in the AD or SIVD group. The intercorrelation matrix of these variables was examined to determine whether any variables were highly correlated (r ≥ 0.80). If this occurred, 1 variable would be selected from the correlated set to avoid multicollinearity. The variables that significantly contributed to the prediction of group membership were identified with forward stepwise regression analysis where P < .05 was used to include variables in the model.
and a specificity of 79% (LR+ = 3.9) when the cutoff value for the predicted probability of having AD was 0.66.

**COMMENT**

In this study we found that 2 tests, one a measure of verbal recognition memory and the other a measure of verbal fluency, distinguished accurately between patients with AD and those with SIVD. A double dissociation was found. The patients with AD performed worse on a recognition memory test than the patients with SIVD, whereas the SIVD group performed worse on the COWAT. Receiver operating characteristic curves were used to identify the optimal cutoff points for each test. The combination of poor recognition and preserved verbal fluency was associated with an LR+ of 5.1 when the cutoff value of the predicted probability of having AD was 0.54. This would generate a moderate change in the pretest-to-posttest likelihood of AD.

The participants in the SIVD subgroup all had subcortical lacunes. However, because 12 of these 31 participants also had cortical infarcts, we replicated the analysis in the smaller group (n = 19) with only subcortical lacunes. In addition to the same 3 variables emerging from the forward logistic analyses, the β coefficients were of a similar magnitude and in the same direction, allowing us to derive the same conclusions from both analyses. However, to further strengthen our findings, cross-validation of the discriminatory variables should be performed in a completely independent sample. In such a study, the β coefficients would be applied to the confirmatory data set, and the predicted probabilities would be correlated with the actual outcomes.

The literature comparing AD with SIVD is limited. In many studies of VaD, patients are not identified by subtype, and group differences in dementia severity, age, and level of education are not adequately controlled. In our study we focused on SIVD, a more homogeneous subgroup of VaD. The 2 groups of patients were similar in age and dementia severity as measured by the MMSE. Education was used as a covariate in all analyses to statistically remove its effects on test scores. Finally, the study was designed to separate the assignment of the target reference groups from the neuropsychological tests, in keeping with evidence-based guidelines for diagnostic tests.21,22

---

**Table 1. Means and SDs of Selected Variables for the Probable Alzheimer Disease and Vascular Dementia Groups**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Alzheimer Disease (N = 31)</th>
<th>Vascular Dementia (N = 31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>76.29 (5.18)</td>
<td>77.07 (6.42)</td>
</tr>
<tr>
<td>Level of education, y</td>
<td>13.16 (2.43)</td>
<td>11.67 (2.58)</td>
</tr>
<tr>
<td>Hachinski Ischemic Scale</td>
<td>1.55 (0.68)</td>
<td>7.68 (1.83)</td>
</tr>
<tr>
<td>MMSE</td>
<td>21.29 (3.57)</td>
<td>22.00 (3.21)</td>
</tr>
<tr>
<td>RAVLT, delayed recall</td>
<td>0.90 (1.64)</td>
<td>1.58 (1.84)</td>
</tr>
<tr>
<td>RAVLT, recognition</td>
<td>66.34 (9.24)</td>
<td>74.52 (10.33)</td>
</tr>
<tr>
<td>COWAT (mean of trials F, A, and S)</td>
<td>9.30 (3.34)</td>
<td>5.47 (2.27)</td>
</tr>
<tr>
<td>Trail Making Test, part A</td>
<td>37.83 (32.8)</td>
<td>61.24 (43.44)</td>
</tr>
<tr>
<td>Trail Making Test, part B</td>
<td>121.16 (59.15)</td>
<td>152.94 (39.97)</td>
</tr>
<tr>
<td>WMS, Logical Memory</td>
<td>2.63 (2.54)</td>
<td>3.61 (2.23)</td>
</tr>
<tr>
<td>WMS, Paired Associates (easy items)</td>
<td>13.35 (3.18)</td>
<td>13.94 (3.45)</td>
</tr>
<tr>
<td>WMS, Paired Associates (hard items)</td>
<td>0.46 (1.46)</td>
<td>1.00 (1.46)</td>
</tr>
<tr>
<td>WMS, Mental Control</td>
<td>4.90 (2.47)</td>
<td>4.61 (2.73)</td>
</tr>
<tr>
<td>Boston Naming Test (odd-even version)</td>
<td>17.93 (6.68)</td>
<td>19.70 (4.48)</td>
</tr>
</tbody>
</table>

*MMSE indicates Mini-Mental State Examination; RAVLT, Rey Auditory Verbal Learning Test (% correct); COWAT, Controlled Oral Word Association Test (letters F, A, and S); and WMS, Wechsler Memory Scale.

---

**Figure 1.** Flow diagram of participants meeting inclusion and exclusion criteria.

**Figure 2.** Receiver operating characteristic curve for the 3-variable model with associated predicted probabilities of having Alzheimer disease.
Our results are consistent with previous patterns noted in the literature. Patients with subcortical ischemic vascular disease tend to show greater impairment in executive function and relatively better preservation of recognition memory.23,24 The COWAT is a widely used test of executive function25 and is considered to measure impairment in the dorsolateral prefrontal system, which is interconnected with the basal ganglia and thalamus in a frontal subcortical loop.2 The specific nuclei include the dorsolateral caudate nucleus, lateral dorsomedial globus pallidus internus, and anterior and dorsomedial nuclei of the thalamus.5,26 Our finding that letter fluency was one of the most critical tests in the battery may indicate that this circuit is frequently disrupted in SIVD at 1 or more of these subcortical loci or in the white matter tracts that interconnect them with the dorsolateral prefrontal lobe. Thus, the results of our study are consistent with earlier findings27,28 that the deficits found in patients with SIVD are primarily due to changes in subcortical structures and in the white matter of the frontal lobe.

It is not surprising that the patients with AD in this study were characterized by deficits in recognition memory. This pattern is well established in the AD literature. Poor recognition memory is considered to reflect deficits in storage caused by deficient consolidation of new memory traces.29 This, in turn, is most often linked to the degeneration of the mesial temporal areas, namely the hippocampus and amygdala. These areas are highly vulnerable to neurofibrillary degeneration, one of the classic neuropathological hallmarks of AD.30,31 Thus, poor recognition memory among patients with AD is likely due to neurofibrillary degeneration in the mesial temporal lobes, including the hippocampus.

This study focuses on a highly selected group of subjects. All patients met either NINCDS-ADRDA criteria for probable AD or NINDS-AIREN criteria for probable VaD modified for SIVD. The latter requires a history of a temporal relationship between a clinical stroke and cognitive decline. Among various available clinical criteria for VaD (Hachinski Ischemic Score, California Alzheimer Disease Diagnostic and Treatment Center criteria, DSM-III-R, and International Classification of Diseases, Ninth Revision), the NINDS-AIREN criteria are the most conservative.32-34 In addition, attempts were made to exclude subjects with mixed AD and VaD. This was done by restricting anyone with vascular lesions on a CT scan from the AD group and excluding stroke subjects without a clearly defined temporal relationship to the onset of dementia from the SIVD group. This selectivity limits the generalizability of our results to typical clinical practice settings where mixed, possible, and other subtypes of VaD are likely to be seen.

How can the results of this study be used to assess the relative likelihood of AD vs SIVD in a clinical setting? After administering the 2 neuropsychological tests, the regression coefficients provided in Table 2 can be used to calculate the probability of having AD. For example, patient A had a grade 12 education, a RAVLT recognition memory score of 60%, and a mean COWAT score of 13 for the 3 trials. The linear combination of the products of the regression coefficients using this patient’s values for educational level, RAVLT recognition, and COWAT would be as follows:

\[
X = (1.05) + (0.23)(12) + (-0.11)(60) + (0.55)(13) = 4.36.
\]

Using the equation

\[
e^x/(1 + e^x),
\]

the predicted probability of AD for patient A would be 0.99.

We would like to caution physicians and neuropsychologists in the appropriate application of this procedure to their patients. First, it should be applied only to those patients who have undergone a thorough clinical workup (apart from a CT scan) to exclude other causes of cognitive impairment and for whom there are only 2 reasonable alternative diagnoses: AD or SIVD. A second caution in the application of these results is that this procedure should be applied only to patients who are similar to the study sample (ie, similar age and educational level, mild to moderate impairment, fluency in English, and the ability to hear normal speech with or without auditory aids). Finally, these tests should be conducted in a controlled, quiet environment by someone trained in their administration and who is skillful with the patient population. Adherence to these 3 recommendations is critical for the proper application of the procedures described in this article.

In conclusion, we illustrate how this type of study may be useful in deciding whether to order a neuroimaging study. In epidemiological studies35 or in managed care settings, neuroimaging may be considered an unnecessary expense.36 It would be useful if neuropsychological test results could identify patients for whom the addition of a neuroimaging study would significantly change the diagnosis or treatment.37 The utility of a diagnostic test (eg, a CT scan) depends not only on its sensitivity and specificity but also on the prior probability of disease.38 A test is less useful if the prior probability is either very low or very high. The results of neuropsychological testing may help to inform ascertainment of this prior probability.

For example, if a patient obtains a low predicted probability of AD after the regression coefficients are applied to his or her test scores and educational level, the patient is likely to have SIVD, and a CT scan should be ordered. If a patient obtains a high predicted probability

<table>
<thead>
<tr>
<th>Variable</th>
<th>Regression Coefficient</th>
<th>P</th>
<th>Odds Ratio</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>1.05</td>
<td>.67</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Level of education</td>
<td>0.23</td>
<td>.04</td>
<td>1.26</td>
<td>1.01-1.57</td>
</tr>
<tr>
<td>RAVLT, recognition</td>
<td>-0.11</td>
<td>.002</td>
<td>0.89</td>
<td>0.83-0.96</td>
</tr>
<tr>
<td>COWAT</td>
<td>0.55</td>
<td>.001</td>
<td>1.74</td>
<td>1.28-2.37</td>
</tr>
</tbody>
</table>

*RAVLT indicates Rey Auditory Verbal Learning Test; COWAT, Controlled Oral Word Association Test; and ellipses, not applicable.
of AD, the decision to order a CT scan will depend on
the magnitude of the probability as well as the preva-
ience of the disease in the clinic (pretest probability).
If the pretest probability of AD is high, one might decide
to forgo the CT scan. If it is low, the test results will have
less of an effect on the posttest probability, and the phy-
sician may still decide to order a CT scan. Future study
is required to evaluate (1) the utility of using neuropsy-
chological test performance to inform the physician about
the prior probability of a disease; and (2) if more accu-
rate assessment of prior probability will provide a cost-
effective basis for deciding whether to order a neuroim-
gaging study.

Accepted for publication July 18, 2001.

This research was supported by the Ontario Ministry of
Health, Toronto, and by grant P01-AG 12435 from the
National Institute on Aging, Bethesda, Md.

Corresponding author and reprints: Mary C. Tierney,
Geriatric Research, A145, Sunnybrook and Women’s Health
Sciences Center, 2075 Bayview Ave, Toronto, Ontario,
Canada M4N 3M5 (e-mail: mary.tierney@swchsc.on.ca).

REFERENCES

14:240-257.
2. Canadian Study of Health and Aging Workgroup. Canadian Study of Health and
Aging: study methods and prevalence of dementia. CMAJ. 1994;150:899-913.
3. Consensus report of the Working Group on Molecular and Biochemical Markers
of Alzheimer’s disease: the Ronald and Nancy Reagan Research Institute of the
Alzheimer’s Association and the National Institute on Aging Working Group. Neu-
4. Rocca W, Hofman A, Brayne C, et al. The prevalence of vascular dementia in Eu-
824.
50:873-880.
6. Sackett DL, Haymes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic
7. Wechsler D. Wechsler Memory Scale-Revised. San Antonio, Tex: Psychological
Corp; 1987.
8. Delis DC, Kramer JH, Kaplan E, Ober BA. CVLT: California Verbal Learning Test:
1987.
& Febiger; 1983.
10. Spreen O, Benton AL. Neurosensory Center Comprehensive Examination for Apha-
11. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York, NY: Psycholo-
gical Corp; 1981.
13. Reitan RM. Manual of Administration of Neuropsychological Test Batteries for
Associates Inc; 1983.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental
Disorders, Revised Third Edition. Washington, DC: American Psychiatric Asso-
ciation; 1987.
diagnosis of Alzheimer’s disease: report of the NINCDS-ADRD A Work Group
under the auspices of Department of Health and Human Services Task Force on
18. Roman GC, Tatemoni TK, Erikenjuti T, et al. Vascular dementia: diagnostic cri-
teria for research studies: report of the NINDS-AIREN International Workshop.
20. Lezak MD. Neuropsychological Assessment. 3rd ed. New York, NY: Oxford Uni-
21. Jaeschke R, Guyatt G, Sackett DL. Users’ guides to the medical literature, Ill:
how to use an article about a diagnostic test, A: are the results of the study valid?
22. Jaeschke R, Guyatt G, Sackett DL. Users’ guides to the medical literature, Ill:
how to use an article about a diagnostic test, B: what are the results and will they
23. Tei H, Miyazaki A, Iwata M, Osaka M, Nagata Y, Murayama S. Early-stage Alz-
heimer’s disease and multiple subcortical infarction with mild cognitive impair-
ment: neuropsychological comparison using and easily applicable test battery.
24. Lafosse J, Reed B, Mungas D, Sterling S, Wahbeh H, Jagust W. Fluency and
memory differences between ischemic vascular dementia and Alzheimer’s dis-
25. Malloy PF, Richardson ED. Assessment of frontal lobe functions. J Neuropsy-
27. Amtkivist O. Neuropsychological deficits in vascular dementia in relation to Alz-
heimer’s disease: reviewing evidence for functional similarity or divergence. De-
28. Libon D, Bogdanoft B, Bonavita J, Skalina S. Dementia associated with periven-
tricular and deep white matter alterations: a subtype of subcortical dementia. Arch
29. Brancionnier RJ, Cole JD, Spera KF, Devitt DR. Recall and recognition as diag-
nostic indices of malignant memory loss in senile dementia: a Bayesian analy-
31. Hyman BT, VanHoesen GW, Damasio AR. Memory-related neural systems in Alz-
32. Verhey F, Lodder J, Rozendaal N, Jolles J. Comparison of seven sets of criteria
used for the diagnosis of Alzheimer’s disease and ischemic vascular dementia.
33. Wetterling T, Kanitz R, Borgis K. Comparison of different diagnostic criteria for
30-36.
dementia: a multicenter study of comparability and interrater reliability. Arch Neu-
35. Rocca W, Kokmen E. Frequency and distribution of vascular dementia. Alzhei-
36. Practice parameter for diagnosis and evaluation of dementia (summary state-
ment): report of the Quality Standards Subcommittee of the American Academy
49:925-935.